Serum levels of cytokeratin 19 fragments in cervical cancer.
Serum levels of a cytokeratin 19 fragment, Cyfra 21-1, were measured using an immunoradiometric assay in 33 women before initial treatment and in 8 women with recurrent tumor. The serum level of Cyfra 21-1 was significantly increased in women with tumors of advanced stage (FIGO) and those with recurrence. The incidence of positivity for Cyfra 21-1 tended to increase with tumor spread. Compared with squamous cell carcinoma (SCC) antigen, the sensitivity of Cyfra 21-1 was comparable to that of SCC antigen. The serum level of Cyfra 21-1 and that of SCC antigen showed a positive correlation. While the use of the serum Cyfra 21-1 level may be limited in cervical cancer by its relatively low sensitivity, a combination assay of Cyfra 21-1 and SCC antigen may be useful in the diagnosis and follow-up of patients with cervical squamous cell carcinoma.
Nasu
K
K
Department of Obstetrics and Gynecology, Oita Medical University, Japan.
Etoh
Y
Y
Yoshimatsu
J
J
Matsu
T
T
Narahara
H
H
Miyakawa
I
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D007633:Keratins / Q000097:blood*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009367:Neoplasm Staging; D010446:Peptide Fragments / Q000097:blood*; D015843:Serpins; D002583:Uterine Cervical Neoplasms / Q000097:blood* / Q000473:pathology
D000951:Antigens, Neoplasm; D010446:Peptide Fragments; D015843:Serpins; C051072:squamous cell carcinoma-related antigen; D007633:Keratins